Cargando…

Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) is the primary cause of death among pulmonary cancer patients. Upregulation of CD80 may interact with cytotoxic T lymphocyte antigen 4 (CTLA4) to promote tumor progression and provide a potential target for biological antitumor therapy. However, the role of CD80 in LUAD is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Wei, He, Ziyi, Shi, Liang, Zhu, Zheng, Ma, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517904/ https://www.ncbi.nlm.nih.gov/pubmed/36892747 http://dx.doi.org/10.1007/s10528-023-10343-7

Ejemplares similares

CC Chemokine Receptors in Lung Adenocarcinoma: The Inflammation-Related Prognostic Biomarkers and Immunotherapeutic Targets
por: Liu, Fangteng, et al.
Publicado: (2021)

Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma
por: Pi, Yilin, et al.
Publicado: (2022)

Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication
por: Sun, Sijin, et al.
Publicado: (2021)

Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

The tumor microenvironment in gastrointestinal adenocarcinomas revealed a prognostic and immunotherapeutic biomarker
por: Zhang, Yong, et al.
Publicado: (2022)

Prognostic and immunotherapeutic significance of immunogenic cell death-related genes in colon adenocarcinoma patients
por: Xu, Jun, et al.
Publicado: (2023)

LINC02126 is a potential diagnostic, prognostic and immunotherapeutic target for lung adenocarcinoma
por: Wang, Junbin, et al.
Publicado: (2022)

Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma
por: Sun, Bao-Ye, et al.
Publicado: (2023)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor
por: Sato, Takashi, et al.
Publicado: (2022)

Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma
por: Wu, Baokang, et al.
Publicado: (2023)

Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma
por: Lin, Weihao, et al.
Publicado: (2021)

GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer
por: Wang, Yunfei, et al.
Publicado: (2023)

GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation
por: Liang, Xuexia, et al.
Publicado: (2023)

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
por: Xu, Feng, et al.
Publicado: (2020)

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
por: Chen, Hongquan, et al.
Publicado: (2022)

A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma
por: Xu, Jiachen, et al.
Publicado: (2023)

Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature
por: Zhang, Pengpeng, et al.
Publicado: (2023)

Infiltration and Significance of CD103+CD8+ T Cells in Gastrointestinal Adenocarcinoma
por: Cai, Weisu, et al.
Publicado: (2022)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker
por: Liu, Weiwei, et al.
Publicado: (2022)

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer
por: Chen, Jiang, et al.
Publicado: (2022)

Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma
por: Du, Minjun, et al.
Publicado: (2021)

SLC7A11, a potential immunotherapeutic target in lung adenocarcinoma
por: Shan, Qingqing, et al.
Publicado: (2023)

WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma
por: Yuan, Qihang, et al.
Publicado: (2021)

ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma
por: Zheng, Yu-Zhu, et al.
Publicado: (2016)

Prognostic and immunotherapeutic significance of mannose receptor C type II in 33 cancers: An integrated analysis
por: Zhao, Zhixun, et al.
Publicado: (2022)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
por: Chouari, Tarak, et al.
Publicado: (2023)

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1
por: Dong, Shiqiang, et al.
Publicado: (2022)

The prognostic significance of fibroblast activation protein-α in human lung adenocarcinoma
por: Shi, Jianlin, et al.
Publicado: (2020)

Prognostic Significance of PTTG1 and Its Methylation in Lung Adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2022)

Hsa_Circ_0066351 Acts as a Prognostic and Immunotherapeutic Biomarker in Colorectal Cancer
por: Gao, Yan, et al.
Publicado: (2022)

IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers
por: Liu, Yutao, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of NCALD protein expression in lung adenocarcinoma
por: Chen, Yi, et al.
Publicado: (2019)

Identification and validation of a novel phagocytosis regulators-related signature with potential prognostic and immunotherapeutic value in patients with lung adenocarcinoma
por: Li, Jingyang, et al.
Publicado: (2022)

Prognostic and diagnostic significance of Cavin 2 in lung adenocarcinoma
por: Wang, Xianguo, et al.
Publicado: (2019)

Prognostic significance of HSF2BP in lung adenocarcinoma
por: Huang, Zhendong, et al.
Publicado: (2021)

Prognostic significance of pyroptosis-related factors in lung adenocarcinoma
por: Lin, Ximing, et al.
Publicado: (2022)

Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer
por: Yang, Kaixin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qn6j1of37mp2a2jq5a09gntlnt